| Literature DB >> 28168081 |
Fabio Granados-Chinchilla1, César Rodríguez2.
Abstract
Antibiotics are widely used as growth promoters in animal husbandry; among them, the tetracyclines are a chemical group of relevance, due to their wide use in agriculture, surpassing in quantities applied almost every other antibiotic family. Seeing the considerable amounts of tetracyclines used worldwide, monitoring of these antibiotics is paramount. Advances must be made in the analysis of antibiotics to assess correct usage and dosage of tetracyclines in food and feedstuffs and possible residues in pertinent environmental samples. The tetracyclines are still considered a clinically relevant group of antibiotics, though dissemination of tolerance and resistance determinants have limited their use. This review focuses on four different aspects: (i) tetracyclines, usage, dosages, and regulatory issues that govern their food-related application, with particular attention to the prohibitions and restrictions that several countries have enforced in recent years by agencies from both the United States and the European Union, (ii) analytical methods for tetracyclines, determination, and residues thereof in feedstuffs and related matrices with an emphasis on the most relevant and novel techniques, including both screening and confirmatory methods, (iii) tetracycline resistance and tetracycline-resistant bacteria in feedstuff, and (iv) environmental and health risks accompanying the use of tetracyclines in animal nutrition. In the last two cases, we discuss the more relevant undesirable effects that tetracyclines exert over bacterial communities and nontarget species including unwanted effects in farmers.Entities:
Year: 2017 PMID: 28168081 PMCID: PMC5266830 DOI: 10.1155/2017/1315497
Source DB: PubMed Journal: J Anal Methods Chem ISSN: 2090-8873 Impact factor: 2.193
Approved applications of tetracyclines in medicated feed for different food-producing animal species and their respective withdrawal time frames.
| Pharmacologically active substance | Indications for usea | Usage level | Withdrawal time (days) |
|---|---|---|---|
|
| |||
|
| |||
|
|
|
|
|
| Reduction of jowl abscesses | 50–100 g ton−1 | Voluntary withdrawal | |
| Control of leptospirosis in sows | 400 g ton−1 | Voluntary withdrawal | |
| Control of proliferative enteropathies (ileitis) | Body weight dosage: 10 mg lb−1 d−1 | Voluntary withdrawal | |
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
| Treatment of bacterial enteritis and bacterial pneumonia | Body weight dosage: 10 mg lb−1 d−1, 7–14 days | None | |
| Control of leptospirosis in sows | Body weight dosage: 10 mg lb−1d−1, 7–14 days | None | |
|
| |||
|
|
|
|
|
| Treatment of bacterial enteritis and bacterial pneumonia | Body weight dosage: 10 mg lb−1 d−1, 7–14 days | 5 | |
| Control and treatment of leptospirosis in breeders | Body weight dosage: 10 mg lb−1 d−1, 7–14 days | 5 | |
|
|
|
| |
|
| |||
|
| Treatment of bacterial enteritis and bacterial pneumonia | 10–25 carbadox; oxytetracycline body weight dosage: 10 mg lb−1 d−1 | 42 |
|
| |||
|
| Control of dysentery; treatment of bacterial enteritis and bacterial pneumonia | 35 tiamulin + 400 CTC (body weight dosage: 10 mg lb−1 d−1) | 2 |
|
| |||
|
| |||
|
| |||
|
| Coacting in the prevention of bacterial pneumonia associated with shipping fever complex caused by | 350 mg head−1 day−1 | 2 |
| Control of active infection of 2 of anaplasmoses caused by | 350 mg head−1 day−1 or 0.5 mg lb−1 of body weight day−1, beef control of active infection | 2 | |
|
| |||
|
| Finishing cattle: to increase rate of gain and improve feed efficiency | 75 mg head−1 day−1 | None |
| Coacting in reducing incidence and severity of liver abscesses | 75 mg head−1 day−1 | None | |
| Coacting in the prevention of bacterial diarrhea | 0.1–0.5 mg lb−1 of body weight day−1 | 0 to 5 | |
| Prophylaxis and treatment of the early stages of shipping fever complex | 0.2–2 mg lb−1 of body weight day−1 | 0 to 5 | |
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
| Coacting in the prevention of bacterial enteritis | From 35 to 140 g ton−1 | 0–7 |
|
| |||
|
| |||
|
| |||
|
|
|
|
|
| Treatment of bacterial enteritis caused by | 10 mg lb−1 of body weight day−1 | None | |
| Treatment of bacterial enteritis caused by | 10 mg lb−1 of body weight day−1 | Variable | |
|
| |||
|
|
|
|
|
| As an aid in the treatment of bacterial diarrhea | From 0.5 to 5.0 mg lb−1 or 35 to 140 g ton−1 | None | |
|
| |||
|
| |||
|
| |||
|
|
| From 10 to 50 g ton−1 | None |
| Control of synovitis caused by | From 100 to 200 g ton−1 | None | |
| To control chronic respiratory disease of the air sacs caused by | 400 g ton−1 | None | |
| To reduce mortality due to air sac infections caused by | 500 g ton−1 | 1 | |
|
| |||
|
| |||
|
| |||
|
| Topical, to treat periodontitis. In dogs, used to treat bacterial infections and infections caused by | NA | NA |
aRows in bold font refer to growth promotion approved applications. Data based on values set in [22, 28]. In USA, tetracyclines are no longer allowed for growth promotion after 1 January 2017.
Requirements of a medicated feed mill license.
| Category I | |||
| Compound(s) | Type A (assay limits,%)a | Type B maximum, g lb−1 (200x, %) | Type B/C (assay limits,%)a |
|
| |||
| Chlortetracycline | 85–115 | 40.0 (8.8) | 80–115/70–130 |
| Oxytetracycline | 90–120 | 20.0 (4.4) | 75–125/65–135 |
|
| |||
| Category II | |||
| Compound(s) | Type A (assay limits, %) | Type B maximum, g lb−1 (100x, %) | Type B/C (assay limits, %) |
|
| |||
| Neomycin | 80–120 | 7.0 (1.54) | 70–125 |
| Oxytetracycline | 80–120 | 10.0 (2.2) | 65–135 |
| Sulfamethazine | 85–115 | 10.0 (2.2) | 80–120 |
| Chlortetracycline | 85–115 | 10.0 (2.2) | 85–125/70–130 |
aPercentage of labeled amount. Based on values set in [28].
Legally bound threshold concentrations established for food commodities or particular animal tissue.
| Pharmacologically active substance | Species | Tissue | Maximum residue limit ( |
|---|---|---|---|
| Chlortetracycline/oxytetracycline/tetracycline | Cattle | Milk ( | 100 |
| Muscle | 200 | ||
| Liver | 600 | ||
| Kidney | 1200 | ||
| Poultry | Muscle | 200 | |
| Liver | 600 | ||
| Kidney | 1200 | ||
| Sheep | Milk ( | 100 | |
| Muscle | 200 | ||
| Liver | 600 | ||
| Kidney | 1200 | ||
| Swine | Muscle | 200 | |
| Liver | 600 | ||
| Kidney | 1200 | ||
| Turkey | Muscle | 200 | |
| Liver | 600 | ||
| Kidney | 1200 | ||
| Fish (i.e., salmonids) | Muscle | 200a | |
| Lobster | Muscle | 200a | |
| Giant prawn ( | Muscle | 200a | |
| Eggs | 400 | ||
| Honey | 300 | ||
|
| |||
| Doxycycline | Cattle, swine, poultry | Muscle | 100 |
| Skin and fat | 300 | ||
| Liver | 300 | ||
| Kidney | 600 | ||
aApplies only to oxytetracycline. Based on values set in [40, 41].
Proficiency parameters for sample pretreatment methods reviewed.
| Treatment | Conditions | Limit of detection | Reproducibility (RSD, %) | Recovery (%) | Detection system | Reference |
|---|---|---|---|---|---|---|
| Ultrasound | 40°C, pH 7.15 | 0.03–0.05 | <4.1 | 81.89–92.42 | LC-UV | [ |
| SPE | Britton-Robinson buffer, 0.008 mol L−1, pH 10 | 4.4–12 | <11.0 | 76.5–95.5 | LC-DAD | [ |
| Pressure | 3 min, 60°C, 65 bars | 10.0–15.0 | <8.4 | 75.6–102.9 | LC-UV | [ |
| MSPE | pH 10.0 | 2–9 | <2.7 | 99.7–101.2 | Capillary electrophoresis | [ |
| SPE | CH3CN/CH3CO2H (8 : 2) | 0.61–10.34 | <7.3 | 81.5–101.4 | [ | |
| MSPD | C6H14, CH3CN : CH2Cl2 (1 : 1) | 7–34 mg kg−1 | <6.1 | 80.6–99.2 | LC-DAD | [ |
| MI-SPE | CH3OH, 70°C, 105 bars | Not indicated | Not indicated | Not indicated | LC-ITMS | [ |
| SPE | CH3CN : CH3OH (1 : 1), 0.1 mol L−1 phosphoric acid | Not indicated | Not indicated | 96–98 | Spectrophotometry | [ |
| SPE | McIlvaine/EDTA buffer | 1.5–8.0 | <3.6 | 70.3–107.4 | DAD | [ |
Performance and conditions of several chromatographic methods developed for tetracycline analysis.
| Sample clean-up | Summary chromatographic conditions | Column | Wavelength(s) (nm) | Limit of detection | Reproducibility (RSD, %) | Recovery (%) | Detection system | Reference |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
|
| ||||||||
| Liquid-liquid extraction/CH3CN/CH2Cl2 petroleum ether | 0.02 mol L−1 H3PO4/0.01 mol L−1 sodium 1-decanesulphonate and CH3CN | PLRP-S, 5 | 355 | 2.2–28.6 ng g−1 | <15.5 | 54–88 | Ion pair-diode array detector (DAD) | [ |
| SPE/Strata-X® (33 | CH3CN, oxalic acid, CH3OH | C18, 3 | 355 | 9.8–27.2 | <12.6 | 55.4–86.3 | UV | [ |
| SPE/Oasis® HLB (100 mg, 3 mL) | CH3CN, oxalic acid, CH3OH | C18, 5 | 350/360/370 | 1.64–4.08 | <9.6 | 83.5–108.6 | DAD | [ |
| SPE/Oasis HLB (100 mg, 3 mL)/Bond Elut® (500 mg, 3 mL) | Trifluoroacetic acid (TFA), CH3CN, CH3OH | XDB C18, 150 × 4.6 mm, 5 | 330 | 3.5–6.5 | <14.4 | 82.1–114.7 | DAD | [ |
|
| ||||||||
|
| ||||||||
|
| ||||||||
| SPE/Oasis HLB (60 and 200 mg) | CH3CN and oxalic acid 0.01 M (pH 2.0). | C8 (100 × 3 mm, |
| 50 | <7.2 | 85.0–92.8 | Fluorescence detector (FLD) | [ |
| SPE/Oasis HLB (30 mg) | oxalic acid, CH3CN | PLRP-S 5 |
| 0.6–1.2 | <9.0 | 84.0–110.0 | FLD | [ |
| Trace enrichment cartridge | CH3CN and oxalic acid | Supersphere RP-8 |
| 11–15 | <5.8 | 90.0–97.0 | UV/FLD/MS | [ |
| SPE/Oasis HLB (200 mg) | CH3CN and oxalic acid | Nucleosil C18 column (5 |
| 50 | <8.0 | 86.0–95.0 | FLD | [ |
| SPE/Oasis HLB (60 mg)/Sep-Pak® C18 (500 mg)/Bond Elut Certify® | CH3CN and 0.01 mol L−1 oxalic acid | Symmetry Shield™ RP8, 150 × 4.6 mm |
| 5.1–34.7 | <12.7 | 61.0–115.0 | FLD | [ |
| SPE/Oasis HLB (30 mg) | 20 mmol L−1 TFA, CH3CN | Zorbax SB C18 column (3 |
| 0.2–500 | <5.0 | 59.0–97.0% | FLD/UV | [ |
| SPE/Oasis HLB (60 mg) | CH3OH/CH3CN/50 mmol L−1 oxalic acid | Luna 5 |
| 2.2 ng g−1 | <5.0 | 75.3–82.5 | FLD | [ |